Waters N, Hansson L, Löfberg L, Carlsson A
Department of Pharmacology, University of Göteborg, Sweden.
Eur J Pharmacol. 1994 Jan 14;251(2-3):181-90. doi: 10.1016/0014-2999(94)90399-9.
The dopamine D3- and autoreceptor preferring antagonists (+)-AJ76 and (+)-UH232 were administered locally in the striatum and the nucleus accumbens. Their effects on dialysate dopamine and 3,4-di-hydroxyphenylacetic acid (DOPAC) were measured and compared with the effects of raclopride. (+)-AJ76 and (+)-UH232 but not raclopride seem to interact primarily with dopamine receptors in the terminal regions of the A9 and A10 dopaminergic fibers to exert their maximal effect on dopamine release in vivo. Thus, (+)-AJ76 and (+)-UH232 seem to recruit different dopamine receptor populations as compared to raclopride. Though the dopamine receptor antagonist-induced effects on dopamine release seem to be mediated mainly by dopamine receptors in the terminal areas, the effects on DOPAC by the different antagonists seem to be mediated mainly via effects elsewhere, presumably at the somatodendritic autoreceptors. Thus, it is suggested that the regulation of extracellular dopamine and DOPAC after treatment with dopamine receptor antagonists are subjected to different control mechanisms.
对多巴胺D3受体及自身受体具有选择性的拮抗剂(+)-AJ76和(+)-UH232被局部注射到纹状体和伏隔核中。测定了它们对透析液中多巴胺和3,4-二羟基苯乙酸(DOPAC)的影响,并与雷氯必利的作用进行了比较。(+)-AJ76和(+)-UH232而非雷氯必利似乎主要与A9和A10多巴胺能纤维终末区域的多巴胺受体相互作用,从而在体内对多巴胺释放发挥最大效应。因此,与雷氯必利相比,(+)-AJ76和(+)-UH232似乎作用于不同的多巴胺受体群体。尽管多巴胺受体拮抗剂对多巴胺释放的作用似乎主要由终末区域的多巴胺受体介导,但不同拮抗剂对DOPAC的作用似乎主要通过其他部位的作用介导,可能是在树突体自身受体处。因此,提示多巴胺受体拮抗剂治疗后细胞外多巴胺和DOPAC的调节受不同的控制机制支配。